Biomarin Pharmaceutical (STU:BM8) Construction In Progress : €0 Mil (As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Construction In Progress?

Biomarin Pharmaceutical's quarterly construction in progress increased from Sep. 2023 (€0 Mil) to Dec. 2023 (€92 Mil) but then declined from Dec. 2023 (€92 Mil) to Mar. 2024 (€0 Mil).

Biomarin Pharmaceutical's annual construction in progress increased from Dec. 2021 (€121 Mil) to Dec. 2022 (€135 Mil) but then declined from Dec. 2022 (€135 Mil) to Dec. 2023 (€92 Mil).

Biomarin Pharmaceutical Construction In Progress Historical Data

The historical data trend for Biomarin Pharmaceutical's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Construction In Progress Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

100.71

89.71

121.02

135.35

91.71

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															-	-	-	91.71	-

Biomarin Pharmaceutical Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Biomarin Pharmaceutical (STU:BM8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (STU:BM8) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (STU:BM8) Headlines

No Headlines